Phase 3 Readout
MAIA: Phase 3 Topline: A Multicenter, Open-label, Randomized Phase 3 Study of THIO Sequenced With Cemiplimab (LIBTAYO®) vs
December 31, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 31, 2027
- Company
- MAIA Biotechnology, Inc. (MAIA)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Multicenter, Open-label, Randomized Phase 3 Study of THIO Sequenced With Cemiplimab (LIBTAYO®) vs
- Indication
- Carcinoma, Non-Small -Cell Lung